Intas Pharmaceuticals Limited — Mitoxantrone Exporter Profile
Indian Pharmaceutical Exporter · #2 for Mitoxantrone · $650.0K export value · DGFT Verified
Intas Pharmaceuticals Limited is the #2 Indian exporter of Mitoxantrone with $650.0K in export value and 13 verified shipments. Intas Pharmaceuticals Limited holds a 34.4% market share in Mitoxantrone exports across 4 countries. The company exports 75 pharmaceutical products worth $372.3M across 19 therapeutic categories.
Intas Pharmaceuticals Limited — Mitoxantrone Export Profile: Buyers & Destinations
Where Does Intas Pharmaceuticals Limited Export Mitoxantrone?
| Country | Value | Shipments | Share |
|---|---|---|---|
| MEXICO | $150.0K | 3 | 56.4% |
| NETHERLANDS | $72.5K | 4 | 27.2% |
| FRANCE | $41.2K | 2 | 15.5% |
| MALTA | $2.4K | 4 | 0.9% |
Intas Pharmaceuticals Limited exports Mitoxantrone to 4 countries. The largest destination is MEXICO accounting for 56.4% of Intas Pharmaceuticals Limited's Mitoxantrone shipments, followed by NETHERLANDS (27.2%) and FRANCE (15.5%). These destinations reflect Intas Pharmaceuticals Limited's established distribution network and regulatory approvals in key markets.
Who Are the Top Buyers of Mitoxantrone from Intas Pharmaceuticals Limited?
| Buyer | Country | Value | Orders |
|---|---|---|---|
| ACCORD FARMA S.A.DE C.V | MEXICO | $100.0K | 2 |
| ALLOGA FRANCE | FRANCE | $94.2K | 5 |
| TO THE ORDER. | MEXICO | $50.0K | 1 |
| SITE D#AMIENS | FRANCE | $19.6K | 1 |
| TO THE ORDER | MALTA | $1.4K | 2 |
| PHARMADOX HEALTHCARE LIMITED | MALTA | $985 | 2 |
Intas Pharmaceuticals Limited supplies Mitoxantrone to 6 buyers globally. The largest buyer is ACCORD FARMA S.A.DE C.V (MEXICO), followed by ALLOGA FRANCE (FRANCE) and TO THE ORDER. (MEXICO). These buyers represent pharmaceutical distributors, hospital groups, and government procurement agencies in their respective markets.
What Is India's Total Mitoxantrone Export Value and How Much Does Intas Pharmaceuticals Limited Contribute?
India exported $944.4K worth of Mitoxantrone through 110 shipments from 42 suppliers to 35 countries, serving 56 buyers globally. Intas Pharmaceuticals Limited contributes $650.0K to this total, accounting for 34.4% of India's Mitoxantrone exports. Intas Pharmaceuticals Limited ships Mitoxantrone to 4 countries through 6 buyers.
What Is the Average Shipment Value for Intas Pharmaceuticals Limited's Mitoxantrone Exports?
Intas Pharmaceuticals Limited's average Mitoxantrone shipment value is $50.0K per consignment, based on 13 shipments totaling $650.0K. The largest destination is MEXICO (56.4% of Intas Pharmaceuticals Limited's Mitoxantrone exports).
How Does Intas Pharmaceuticals Limited Compare to Other Indian Mitoxantrone Exporters?
Intas Pharmaceuticals Limited ranks #2 among 42 Indian Mitoxantrone exporters with a 34.4% market share. The top 3 exporters are INTAS PHARMACEUTICALS LIMITED ($650.0K), MVL GLOBAL ($150.0K), MEDWISE OVERSEAS PRIVATE LIMITED ($76.3K). Intas Pharmaceuticals Limited processed 13 shipments to 4 destination countries.
What Mitoxantrone Formulations Does Intas Pharmaceuticals Limited Export?
| Product Description / Formulation | Value | Shipments |
|---|---|---|
| PH.DRU.&MED: BRESNIX MITOXANT 20MG/10ML 1X1V ACC MEX Each mL contains: Mitoxantrone hydroc. Ph. Eur equ.to Mitoxant. 2mg | $50.0K | 1 |
| PHARMA.DRUGS & MEDICINE BRESNIX MITOXANT20MG/10ML 1X1V ACC MEX EACH ML CONT.MITOXANTRONE HYDROCHLORIDE PH.EUR.EQUIVALEN | $50.0K | 1 |
| PHARMA.DRUGS & MEDICINE BRESNIX MITOXANT20MG/10ML 1X1V ACC MEX EACH ML CONTS.MITOXANTRONE HYDROCHLORIDE PH.EUR.EQUIVALE | $50.0K | 1 |
| PHA.DRU & MEDI MITOXANTRONE2MG/ML5MLX1V(ACCORD-FRANCE EACH ML CONTAINS : MITOXANTRONE HYDROCHLORIDE PH.EUR. EQ. TO MINOS | $41.2K | 2 |
| PHARMA DRUGS & MEDI MITOXANTRONE,2MG/ML,5MLx1V(ACCORD-FRANCE AS PER INVOICE | $37.6K | 2 |
| PHARMA DRUGS MEDI MITOXANTRONE 2MG ML 5MLx1V ACCORD FRANCE AS PER INVOICE | $34.9K | 2 |
| PHARMA DRUGS & MEDI: MITOXANTRONE,2MG/ML,5MLx1V (ACCORD-FRANCE 26X1X1VIAL | $710 | 1 |
| PHARMA DRUGS & MEDI: MITOXANTRONE,2MG/ML,5MLx1V(ACCORD-FRANCE 26X1X1VIAL | $673 | 1 |
| PHARMA DRUGS & MEDI: MITOXANTRONE2MG/ML5MLX1V(ACCORD-FRANCE 26X1X1VIALNOS | $498 | 1 |
| PHARMA DRUGS & MEDI: MITOXANTRONE2MG/ML5MLX1V (ACCORD-FRANCE 26X1X1VIALNOS | $486 | 1 |
Intas Pharmaceuticals Limited exports 10 distinct Mitoxantrone formulations including tablets, capsules, syrups, and combination drugs. The top formulation is PH.DRU.&MED: BRESNIX MITOXANT 20MG/10ML 1X1V ACC MEX Each mL with 1 shipments worth $50.0K.
Regulatory Requirements: Exporting Mitoxantrone to Key Markets
What Intas Pharmaceuticals Limited must comply with to export Mitoxantrone to its top destination countries
Mexico — COFEPRIS
Approval Process
Generic registration under Mexican health law. NOM standards apply.
Timeline: 12–18 months
GMP & Export Requirements
Mexican GMP (NOM-059-SSA1); COFEPRIS overseas inspection or PIC/S certificate
Sanitary Import Permit from COFEPRIS; import licence via SAT
Note: COFEPRIS participates in PIC/S, easing recognition of PIC/S certificates from Indian authorities.
Regulatory information is provided for general reference based on publicly available guidelines. Requirements vary by formulation, dosage form, and therapeutic classification. Exporters should consult qualified regulatory affairs professionals for case-specific guidance.
How Does Intas Pharmaceuticals Limited Compare to Nearest Mitoxantrone Exporters?
Exporters ranked immediately above and below #2 by export value
| # | Supplier | Export Value | Shipments | Countries | Avg/Shipment |
|---|---|---|---|---|---|
| 2 | INTAS PHARMACEUTICALS LIMITED ★ | $650.0K | 13 | 4 | $50.0K |
| 1 | MVL GLOBAL | $150.0K | 3 | 1 | $50.0K |
| 3 | MEDWISE OVERSEAS PRIVATE LIMITED | $76.3K | 3 | 1 | $25.4K |
Intas Pharmaceuticals Limited ranks #2 among 42 Indian Mitoxantrone exporters. Average shipment value of $50.0K compared to the market average of $22.5K. The closest competitors by value are MVL GLOBAL and MEDWISE OVERSEAS PRIVATE LIMITED.
Which Indian Ports Ship Mitoxantrone Exports?
| Port | Shipments | % Share |
|---|---|---|
| SAHAR AIR CARGO ACC (INBOM4) | 28 | 25.5% |
| SAHAR AIR | 28 | 25.5% |
| DELHI AIR CARGO ACC (INDEL4) | 14 | 12.7% |
| Bombay Air | 7 | 6.4% |
| DELHI AIR | 4 | 3.6% |
| AHEMDABAD AIR | 3 | 2.7% |
| COCHIN AIR | 3 | 2.7% |
| Bombay Air Cargo | 3 | 2.7% |
Geopolitical & Trade Policy Impact on Intas Pharmaceuticals Limited's Mitoxantrone Exports
The current geopolitical landscape presents both challenges and opportunities for Indian pharmaceutical exporters like Intas Pharmaceuticals. The Israel-Iran tensions have led to increased security risks in the Strait of Hormuz and the Red Sea–Suez Canal corridor, prompting major carriers to reroute shipments around the Cape of Good Hope. This detour has extended transit times by 10–20 days and raised freight rates by 40–50% on key India–Europe routes, impacting the cost-effectiveness and timeliness of exports. (livemint.com)
Conversely, the ongoing US-China trade tensions have opened avenues for Indian pharmaceutical companies to capture a larger share of the U.S. market. Intas's acquisition of UDENYCA® and the FDA's acceptance of its biosimilar applications position the company to leverage these opportunities effectively. However, compliance with the European Union's Falsified Medicines Directive (FMD) remains a critical factor for market access. Intas's proactive approach in securing partnerships and ensuring regulatory compliance underscores its commitment to maintaining and expanding its presence in the European market.
Intas Pharmaceuticals Limited — Regulatory Compliance & Quality Standards
Maintaining stringent regulatory compliance is paramount for Indian pharmaceutical exporters. Intas Pharmaceuticals has demonstrated a strong commitment to adhering to international quality standards, as evidenced by its successful acquisitions and partnerships that necessitate compliance with FDA, WHO, and EU Good Manufacturing Practices (GMP). The company's proactive engagement in regulatory processes, such as the FDA's acceptance of its Biologics License Application for DMB-3115, reflects its dedication to quality and compliance. (intaspharma.com) As global regulatory requirements continue to evolve, Intas's focus on quality assurance and compliance positions it favorably in the competitive pharmaceutical export market.
About Intas Pharmaceuticals Limited
Intas Pharmaceuticals Limited exports 75 products worth $372.3M. Beyond Mitoxantrone, top products include Ras, Mycophenolate, Tacrolimus, Apixaban, Ezetimibe. View the complete Intas Pharmaceuticals Limited profile for full portfolio analysis.
Market Intelligence
Latest developments and market context
Detailed market intelligence for Mitoxantrone — including regulatory updates, trade policy changes, and competitive landscape analysis — will be available in an upcoming update. This section will feature AI-researched insights from verified industry sources, government notifications, and market reports.
Official References & Regulatory Resources
- CDSCO India
- Pharmexcil
- IBEF — India Pharma Industry
- Ministry of Commerce — Pharma Exports
- India Trade Statistics (DGFT)
Verify manufacturer licensing and export certifications with the official agencies above.
Research Methodology & Data Transparency
Suresh Sormare
Verified AuthorPharmaceutical Export-Import Analyst & Trade Intelligence Expert
Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.
linkedin.com/in/sureshsormarePrimary Data Source
All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.
Analysis Methodology
- 1.Product Matching: Mitoxantrone shipments identified using fuzzy matching on DGFT product description fields, validated against Indian Pharmacopoeia nomenclature.
- 2.Supplier Identification: Intas Pharmaceuticals Limited matched across shipments using name normalization, accounting for company name formatting variations.
- 3.Statistical Normalization: Shipment values are statistically normalized to ensure accurate market share representation. This removes the impact of unusually large one-off transactions that could distort company rankings.
- 4.Verified Records: This page is backed by 13 individual customs records matching Intas Pharmaceuticals Limited exporting Mitoxantrone, covering 10 formulations to 4 countries via 6 buyers.
Government-Sourced Data
Official DGFT customs records
Transparent Methodology
Calculations fully disclosed above
Global Coverage
Exports to 35+ countries, 56+ buyers
Expert-Reviewed
Analyzed by pharmaceutical trade specialists
Get Mitoxantrone Export Data from Intas Pharmaceuticals Limited
Access shipment-level details, pricing data, buyer connections, and competitive analysis for Intas Pharmaceuticals Limited's Mitoxantrone exports. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.
Intas Pharmaceuticals Limited
Full Company Profile →
75 products · $372.3M total trade · 19 categories
Mitoxantrone Stats
Company Overview
Top Products by Intas Pharmaceuticals Limited
Related Analysis
Need Detailed Export Data?
Access shipment-level records, pricing trends, and buyer contacts for Intas Pharmaceuticals Limited.
Request DemoView Pricing →Data Source
Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports for Mitoxantrone. For current shipment-level data, contact TransData Nexus.